| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
MWCL-1 was established as LPL cell line. MWCL-1 cells were classified into three subpopulations by flow cytometric analyses using anti-CD20 and anti-CD138 antibodies: CD20－CD138－, CD20＋CD138－, and CD20＋CD138＋ cells. We searched for markers preferentially expressed in CD20－CD138－ cells of MWCL-1 (the candidates for tumor-initiating cells of LPL), and the chemokine receptor CXCR7 was isolated. We also searched for favorable microenvironments for their proliferation, and we found that hypoxia and CXCL12-CXCR7 signaling appeared to be favorable microenvironments. We then examined the effect of plasma-activated medium (PAM) on LPL cell line, and we found that PAM induced plasma cell (CD138 positive) differentiation, which appeared to be mediated by PRDM1α (the transcription factor promoting plasma cell differentiation).
|
